AMAG enters definitive merger contract with Allos Therapeutics AMAG Pharmaceuticals read more.

AMAG enters definitive merger contract with Allos Therapeutics AMAG Pharmaceuticals, Inc. and Allos Therapeutics, Inc. today announced they have entered into a definitive merger agreement under which the companies will combine within an all-share merger with a complete equity value of around $686 million read more . The transaction is likely to result in annual cost benefits synergies of between $55 million and $60 million, the majority of which are anticipated to be noticed in the first fiscal calendar year after closing. Under the conditions of the transaction, which has been approved by the boards of directors of both companies, Allos stockholders will receive a set ratio of 0.1282 shares of AMAG common stock for every share of Allos common stock they own.